Top 12 Ketamine for Mental Health Papers

This review explains why ketamine changed depression research. Its value is that it connects the early clinical signal to a broader shift in thinking: antidepressant effects do not have to come only through monoamine pathways, and rapid changes in glutamate, GABA, and cortico-limbic systems may also matter.

This review is useful because it separates ketamine into its two mirror-image forms, esketamine and arketamine, instead of treating the drug as one simple intervention. It helps readers understand why formulation, route, side effects, and mechanism have become central questions in ketamine treatment.

This mechanisms review moves beyond the simple idea that ketamine works only by blocking NMDA receptors. It walks through downstream pathways, metabolites, neuroplasticity, and brain-network changes, making it a useful anchor for understanding why ketamine can act quickly and why its effects may differ from standard antidepressants.

This imaging study links ketamine's subjective dissociative effects to glutamate release and changes in brain activity. It matters because it gives a biological handle on an experience patients can feel directly, helping connect ketamine's altered-state effects to the neural mechanisms researchers think may support antidepressant action.

This randomized trial helped make ketamine important for suicide-related research. It tested whether a single infusion could rapidly reduce suicidal thoughts in people with major depression, a question with immediate clinical stakes. The paper is especially useful because it separates rapid crisis relief from the slower work of sustained depression treatment.

This study compares ketamine with electroconvulsive therapy, one of the strongest existing treatments for severe depression. It is useful because it asks a practical clinical question rather than only a mechanistic one: whether ketamine can produce fast antidepressant effects while avoiding some of the cognitive tradeoffs associated with ECT.

This meta-analysis tackles a question clinicians and patients now face directly: whether racemic ketamine and esketamine should be treated as interchangeable. It brings together trial evidence on response, tolerability, and dropout, making it a useful map of where the formulation debate stands and where the evidence is still uneven.

This trial extends ketamine research beyond depression into chronic PTSD. Its value is that it tests repeated dosing rather than a single infusion, showing both why ketamine looked promising for trauma symptoms and why durability remains a central question when the acute response fades.

This review shows why ketamine entered addiction research: not only because it can change mood, but because it may affect craving, memory reconsolidation, neuroplasticity, and relapse risk. It is a useful bridge between pharmacology and psychotherapy, while also making clear that much of the evidence is still early.

This review compares ketamine with classic serotonergic psychedelics through the lens of rapid antidepressant action. It is useful because it highlights possible shared downstream mechanisms, especially glutamate and plasticity, while keeping the important differences between dissociative and serotonergic drugs in view.

This EEG study asks whether ketamine can restore sensitivity to prediction errors in depression. That makes it interesting as a mechanism paper: instead of only measuring symptom change, it tests whether ketamine can shift a learning signal that may be weakened by rumination, fatigue, and rigid expectations.

This review brings ketamine into palliative care, where pain, depression, anxiety, and serious illness often overlap. It is useful because the evidence is mixed rather than simple: depression outcomes look more consistent than pain outcomes, and route, dose, and treatment schedule appear to matter.